Lycorine could ameliorate hepatic steatosis, OS and ferroptosis in MASLD mice by inhibiting the expression of phosphorylated EGFR, which in turn inhibited the PI3K/AKT signaling pathway. Here, AKT1 is linked to fatty liver disease.